Fluciclovine F-18 clinical trials
Also written Axumin and FACBC.
How each study uses fluciclovine F-18 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the fluciclovine F-18 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- 21 May 2017 · Axumin · EMEA/H/C/004197 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
37 studies that test it; most in 2019 (6)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 3 |
| 2013 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 6 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 32
Emory University (5) · Blue Earth Diagnostics (4) · David M. Schuster, MD (4) · Baptist Health South Florida (3) · University of Utah (2) · Memorial Sloan Kettering Cancer Center (2) · Children's Hospital of Philadelphia (2) · OHSU Knight Cancer Institute (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5
Studies that test fluciclovine F-18.
- Dec 202618F-Fluciclovine PET-MRI in High-grade GliomaEarly Phase 1 · Children's Hospital of Philadelphia
- Dec 2026Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PETPhase 4 · OHSU Knight Cancer Institute
- Mar 2027Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic RadiosurgeryPhase 1 · Baptist Health South Florida
- Sep 2027Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CTPhase 1 · Brigham and Women's Hospital
- Oct 2027Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of GlioblastomaEarly Phase 1 · Abramson Cancer Center at Penn Medicine
Studies
Open first, then newest update. How each study uses fluciclovine F-18 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 37
- 18F-Fluciclovine PET/CT in Multiple MyelomaRecruitingPhase 2National Cancer Institute (NCI)NCT06103838Written as 18F-fluciclovine injection
- Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical RecurrenceRecruitingPhase 4Blue Earth DiagnosticsNCT07569926Written as fluciclovine (18F)
- Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CTRecruitingPhase 1Brigham and Women's HospitalNCT06062745Written as 18F-fluciclovine
- Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGGRecruitingEarly Phase 1Children's Hospital of PhiladelphiaNCT05555550Written as 18F-Fluciclovine
- Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of GlioblastomaRecruitingEarly Phase 1Abramson Cancer Center at Penn MedicineNCT06613841Written as Fluciclovine F18
- 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic RadiosurgeryRecruitingPhase 1Baptist Health South FloridaNCT06048094Written as 18F fluciclovine
- Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic RadiosurgeryRecruitingPhase 1Baptist Health South FloridaNCT04689048Written as 18F fluciclovine
- 18F-Fluciclovine PET-MRI in High-grade GliomaRecruitingEarly Phase 1Children's Hospital of PhiladelphiaNCT05553041Written as 18F-Fluciclovine PET-MRI
- Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain MetastasisRecruitingPhase 2Baptist Health South FloridaNCT05554302Written as 18F-Fluciclovine
- Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer OutcomesActive, not recruitingPhase 2Emory UniversityNCT03762759Written as Fluciclovine F18
- Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PETActive, not recruitingPhase 4OHSU Knight Cancer InstituteNCT05722925Written as Fluciclovine PET/CT
- 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging TherapiesCompletedPhase 2Tulane UniversityNCT04158245Written as 18F-fluciclovine PET Scan
- Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain MetastasesCompletedPhase 3Blue Earth DiagnosticsNCT04410133Written as 18F fluciclovine
- Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)CompletedPhase 2Blue Earth DiagnosticsNCT04410367Written as 18F fluciclovine
- Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast CancerCompletedPhase 1Emory UniversityNCT04750473Written as Fluciclovine F18
- An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate CancerTerminatedPhase 4M.D. Anderson Cancer CenterNCT04134208Written as Fluciclovine F18
- Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the BoneCompletedPhase 2University of UtahNCT03707184Written as Fluciclovine F18
- 18F-Fluciclovine PET/CT in the Assessment of Pancreatic TransplantsCompletedEarly Phase 1University of UtahNCT04852523Written as 18F-fluciclovine
- 18F-Fluciclovine PET and Multiparametric MR ImagingWithdrawnPhase 2Loma Linda UniversityNCT03925675Written as PET/CT with F-Fluciclovine (Axumin)
- FACBC Outcomes for Post ProstatectomyCompletedPhase 2/3Emory UniversityNCT01666808Written as FACBC
Codes
What other systems call fluciclovine F-18 · ClinicalTrials.gg INT004135
- MeSH (NLM) C117460fluciclovine F-18Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 38R1Q0L1ZEFLUCICLOVINE F-18Confirmed FDA, NLM
- RxNorm 1796118One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C117460 | fluciclovine F-18 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 38R1Q0L1ZE | FLUCICLOVINE F-18 | Confirmed FDA, NLM |
| RxNorm | 1796118 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.